Fucosylated glycoproteomic approach to identify a complement component 9 associated with squamous cell lung cancer (SQLC)

Journal of Proteomics

Volumn 74, Issue 12, 2011, Pages 2948-2958

  Narayanasamy, Arul ^a   Ahn, Jung Mo ^a   Sung, Hye Jin ^a   Kong, Deok Hoon ^b   Ha, Kwon Soo ^b   Lee, Soo Youn ^c   Cho, Je Yoel ^a  

^a Kyungpook National University   (South Korea)

^b Kangwon National University   (South Korea)

^c Samsung Medical Center   (South Korea)

Author keywords

Complement component 9; Fucosylation; Serum; Squamous cell lung cancer

Indexed keywords

BOVINE SERUM ALBUMIN; COMPLEMENT COMPONENT C9; IMMUNOGLOBULIN G;

ADULT; AGED; ANTIBODY AFFINITY; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER PATIENT; CONTROLLED STUDY; DEGLYCOSYLATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FUCOSYLATION; HUMAN; LIVER CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG SMALL CELL CANCER; MALE; METASTASIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DEPLETION; PROTEIN MICROARRAY; PROTEIN MODIFICATION; PROTEOMICS; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; SMOKING; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; COMPLEMENT C9; FUCOSE; GLYCOPROTEINS; GLYCOSYLATION; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASMS, SQUAMOUS CELL; TUMOR MARKERS, BIOLOGICAL;

EID: 81055156990     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2011.07.019     Document Type: Article

References (34)

1. Granville C.A., Dennis P.A. An overview of lung cancer genomics and proteomics. Am J Respir Cell Mol Biol 2005, 32:169-176.
2. Wallace W.A. The challenge of classifying poorly differentiated tumours in the lung. Histopathology 2009, 54:28-42.
3. Travis W.D. Pathology of lung cancer. Clin Chest Med 2002, 23:65-81. viii.
4. Pretreatment evaluation of non-small-cell lung cancer. The American Thoracic Society and The European Respiratory Society. Am J Respir Crit Care Med 1997, 156:320-332.
5. Parkin D.M. Global cancer statistics in the year 2000. Lancet Oncol 2001, 2:533-543.
6. Gail M.H., Muenz L., McIntire K.R., Radovich B., Braunstein G., Brown P.R., et al. Multiple markers for lung cancer diagnosis: validation of models for localized lung cancer. J Natl Cancer Inst 1988, 80:97-101.
7. Cho W.C. Potentially useful biomarkers for the diagnosis, treatment and prognosis of lung cancer. Biomed Pharmacother 2007, 61:515-519.
8. Heo S.H., Lee S.J., Ryoo H.M., Park J.Y., Cho J.Y. Identification of putative serum glycoprotein biomarkers for human lung adenocarcinoma by multilectin affinity chromatography and LC-MS/MS. Proteomics 2007, 7:4292-4302.
9. Rudd P.M., Dwek R.A. Glycosylation: heterogeneity and the 3D structure of proteins. Crit Rev Biochem Mol Biol 1997, 32:1-100.
10. Radziejewska I., Borzym-Kluczyk M., Kisiel D.G., Namiot Z., Wosek J., Gindzienski A. Characterisation of glycoforms of ascitic fluids in benign and malignant diseases. Clin Biochem 2009, 42:72-77.
11. Arnold J.N., Saldova R., Hamid U.M., Rudd P.M. Evaluation of the serum N-linked glycome for the diagnosis of cancer and chronic inflammation. Proteomics 2008, 8:3284-3293.
12. An H.J., Kronewitter S.R., de Leoz M.L., Lebrilla C.B. Glycomics and disease markers. Curr Opin Chem Biol 2009, 13:601-607.
13. Jia W., Lu Z., Fu Y., Wang H.P., Wang L.H., Chi H., et al. A strategy for precise and large scale identification of core fucosylated glycoproteins. Mol Cell Proteomics 2009, 8:913-923.
14. Miyoshi E., Ihara Y., Hayashi N., Fusamoto H., Kamada T., Taniguchi N. Transfection of N-acetylglucosaminyltransferase III gene suppresses expression of hepatitis B virus in a human hepatoma cell line, HB611. J Biol Chem 1995, 270:28311-28315.
15. Keller A., Nesvizhskii A.I., Kolker E., Aebersold R. Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem 2002, 74:5383-5392.
16. Nesvizhskii A.I., Keller A., Kolker E., Aebersold R. A statistical model for identifying proteins by tandem mass spectrometry. Anal Chem 2003, 75:4646-4658.
17. Jung J.W., Jung S.H., Yoo J.O., Suh I.B., Kim Y.M., Ha K.S. Label-free and quantitative analysis of C-reactive protein in human sera by tagged-internal standard assay on antibody arrays. Biosens Bioelectron 2009, 24:1469-1473.
18. Chong PK, Lee H, Loh MC, Choong LY, Lin Q, So JB, et al. Upregulation of plasma C9 protein in gastric cancer patients. Proteomics. 2010;10:3210-21.
19. Jemal A., Siegel R., Ward E., Murray T., Xu J., Thun M.J. Cancer statistics, 2007. CA Cancer J Clin 2007, 57:43-66.
20. Nakagawa T., Uozumi N., Nakano M., Mizuno-Horikawa Y., Okuyama N., Taguchi T., et al. Fucosylation of N-glycans regulates the secretion of hepatic glycoproteins into bile ducts. J Biol Chem 2006, 281:29797-29806.
21. Lai CH, Chang NW, Lin CF, Lin CD, Lin YJ, Wan L, et al. Proteomics-based identification of haptoglobin as a novel plasma biomarker in oral squamous cell carcinoma. Clin Chim Acta. 2010;411:984-91.
22. Kang X, Sun L, Guo K, Shu H, Yao J, Qin X, et al. Serum protein biomarkers screening in HCC patients with liver cirrhosis by ICAT-LC-MS/MS. J Cancer Res Clin Oncol. 2010;136:1151-9.
23. Matsumoto H, Shinzaki S, Narisada M, Kawamoto S, Kuwamoto K, Moriwaki K, et al. Clinical application of a lectin-antibody ELISA to measure fucosylated haptoglobin in sera of patients with pancreatic cancer. Clin Chem Lab Med. 2010;48:505-12.
24. Kang SM, Sung HJ, Ahn JM, Park JY, Lee SY, Park CS, et al. The Haptoglobin beta chain as a supportive biomarker for human lung cancers. Molecular bioSystems. 2011;7:1167-75.
25. Zhao Q., Duan W., Wu Y.M., Qian X.H., Deng X.H. Analysis of serum biomarkers of ovarian epithelial cancers based on 2-DE DIGE and MALDI TOF/TOF. Zhonghua Zhong Liu Za Zhi 2008, 30:754-758.
26. Abd Hamid U.M., Royle L., Saldova R., Radcliffe C.M., Harvey D.J., Storr S.J., et al. A strategy to reveal potential glycan markers from serum glycoproteins associated with breast cancer progression. Glycobiology 2008, 18:1105-1118.
27. Li Z.G., Zhao L., Liu L., Ding Y.Q. Monitoring changes of serum protein markers in metastatic colorectal carcinoma model. Zhonghua Bing Li Xue Za Zhi 2007, 36:48-52.
28. El-Akawi ZJ, Abu-Awad AM, Sharara AM, Khader Y. The importance of alpha-1 antitrypsin (alpha1-AT) and neopterin serum levels in the evaluation of non-small cell lung and prostate cancer patients. Neuro Endocrinol Lett. 2010;31:113-6.
29. Sun Z.L., Zhu Y., Wang F.Q., Chen R., Peng T., Fan Z.N., et al. Serum proteomic-based analysis of pancreatic carcinoma for the identification of potential cancer biomarkers. Biochim Biophys Acta 2007, 1774:764-771.
30. Chatterji B., Borlak J. Serum proteomics of lung adenocarcinomas induced by targeted overexpression of c-raf in alveolar epithelium identifies candidate biomarkers. Proteomics 2007, 7:3980-3991.
31. Ryu J.W., Kim H.J., Lee Y.S., Myong N.H., Hwang C.H., Lee G.S., et al. The proteomics approach to find biomarkers in gastric cancer. J Korean Med Sci 2003, 18:505-509.
32. Liszewski M.K., Farries T.C., Lublin D.M., Rooney I.A., Atkinson J.P. Control of the complement system. Adv Immunol 1996, 61:201-283.
33. Lichtenfeld J.L., Wiernik P.H., Mardiney M.R., Zarco R.M. Abnormalities of complement and its components in patients with acute leukemia, Hodgkin's disease, and sarcoma. Cancer Res 1976, 36:3678-3680.
34. Murakoshi Y, Honda K, Sasazuki S, Ono M, Negishi A, Matsubara J, et al. Plasma biomarker discovery and validation for colorectal cancer by quantitative shotgun mass spectrometry and protein microarray. Cancer science. 2011;102:630-8.